Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 1,001–1,086 of 1,086
Eeshwar, S. (2026) · American journal of student research. · doi:10.70251/hyjr2348.45740749
Khan, M. D., haq, M. S. U., Shaukat, M. I., Khan, M. A., shahzad, S., shahzad, S., Jamil, M., & farooq, F. (2026) · Cardiology in the Young · doi:10.1017/s1047951126124317
Yılmaz, S., Karaman, K., Ozsoy, Z., & Çelik, A. (2026) · Medicina · doi:10.3390/medicina62101896
“A recent Heart Failure Association statement identifies obesity-related heart failure with preserved ejection fraction as a distinct phenotype that responds to large weight loss [9,10].”
Hu, F. B., Beleslin, B., Blaha, M. J., Kris-Etherton, P. M., Seligman, H. K., & Williams, K. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.025 · Cited by 1
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
“SUMMIT further supported metabolic and functional benefits while leaving long-term prognostic effects uncertain (21).”
2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure
Chopra, V., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D., Burgos, L. M., Butler, J., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.09.001 · Cited by 1
Wang, H., Li, Y., Qin, C., Chen, X., Wang, K., Zhang, M., & Cheng, W. (2026) · iScience · doi:10.1016/j.isci.2026.117553 · Cited by 1
Lu, G., Wang, X., Zhuang, H., Wang, X., Zhou, X., & Zhao, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179387
O’Leary, C., Alabdallah, K., Shahab, S., Love, A., & Khalife, W. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7552826
Engineering the geriatric heart to model HFpEF
Bass-Stringer, S., Lees, J. G., & Lim, S. Y. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10683-7
“Sebastian Bass-Stringer 1,2 · Jarmon G. Lees 1,2,3 · Shiang Y. Lim 1,2,3,4 endpoint of cardiovascular death or worsening heart failure events [2–5 ].”
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Self-citationMapping the Scientific Landscape of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Obesity Treatment
Santos, B. R. D. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ballatore, A., Poggio, A., Sullivan, A. P., Saglietto, A., Ferrari, G. M. D., & Anselmino, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030969
“In the SUMMIT trial, tirzepatide showed a reduction in the risk of cardiovascular death and worsening HF, together with better exercise tolerance in patients with obesity-related HFpEF [90].”
Drugs Used in the Treatment of Obesity – A Systematic Review
Plinta, O., Bednarek, F., Hojda, A., Małajewicz, I., Nawrocka, N., Oskroba, K., Pietrzyk, M., Rodak, H., & Stępień, D. (2026) · Quality in Sport · doi:10.12775/qs.2026.51.67976
Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis
Park, B. (2025) · TSpace (University of Toronto)
Atwood, T. R. (2026) · WakeSpace Scholarship (Wake Forest University)
Текеева, М. И., Тамбиева, З. А., & Кочкаров, Ш. А. (2026) · Международный журнал гуманитарных и естественных наук
Heart failure prevention in central adiposity and preclinical left ventricular systolic impairment
Lee, M. M. Y., & Lam, C. S. P. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag409
Marshall, W. R., Sinha, S., Green, D., & Kalra, P. A. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001225
Goktas, S. S., Francisco, A., Duarte, J. M. N., Meißner, A., & Magnusson, M. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00204.2026
Xavier, H. T. (2026) · Unisanta Health Science · doi:10.5281/zenodo.22874152
2024 - Pros and cons in general internal medicine and geriatrics
Cucinotta, D. (2025) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v96i1.16806
Inciardi, R. M., Abdin, A., Abdelhamid, M., Ambrosio, G., Böhm, M., Cannata, A. N., Chioncel, O. D., Cosentino, F., Esteban‐Fernández, A., Elsanhoury, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag301
ALNAWMASI, M. S., Albalawi, W. S., Hayyan, M. Y., ALHARBI, M. S. S., & ALOTAIBI, M. A. R. (2025) · TPM Testing, psychometrics, methodology in applied psychology
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
“Agents studied in these trials, including higher-dose semaglutide (2.4 mg) and the dual GLP-1/GIP receptor agonist tirzepatide, have been associated with improvements in heart failure-related outcomes [29, 36, 59].”
InfluentialInnovative holistic treatment for CKM: what lies ahead?
Balfanz, P., & Marx, N. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107222
Epelde, F. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1956165
Cardiovascular promise requires endpoint discipline: interpreting tirzepatide after SURPASS-CVOT
Vijayasimha, M., & Wadhwa, T. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261497184
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830 · Cited by 1
Prokopidis, K., Joshi, A. S., Gam, S., Norman, K., Müller‐Werdan, U., Doehner, W., & Langer, H. T. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00780-x
“For GLP-1 medicines, in turn, a prominent weight loss in HFpEF patients with obesity has been observed, reaching anywhere between 10 and 15 kg [36, 37].”
U.S. Trends in 10-Year Cardiovascular Risk Scores Over 2 Decades
Drexler, Y. R., Goldwasser, O., McCarley, C., Land, D., Naranjo, C., Mechery, V., Kulandavelu, S., Rundek, T., Yang, E., & Elfassy, T. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103307 · Cited by 1
Dziewierz, A., Krawczyk‐Ożóg, A., Szarpak, Ł., Kowalska‐Bobko, I., & Siudak, Z. (2026) · Advances in Medical Sciences · doi:10.1016/j.advms.2026.10.005
Sakata, Y., Matsuoka, Y., 後岡広太郎, Kyodo, A., Kohsaka, S., Obokata, M., Nagai, T., Anzai, T., Ohtani, T., Yoshio, Y., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0356
Qureshi, S., Sajid, M., Khan, H. R., Greene, S. J., Fudim, M., McCann, G. P., Squire, I. B., Waqas, S. A., Khan, M. S., Lawson, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.10.001
Qi, Z., Xu, T., Yang, C., & Tan, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1976969
“Tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure and improved health status in the SUMMIT trial (89).”
Matteucci, A., Bonanni, M., Sgarra, L., Nesti, L., Mariani, M. V., Pierucci, N., Cersosimo, A., Pittorru, R., Nardi, F., & Colivicchi, F. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13100512
“In the SUMMIT trial, tirzepatide reduced the composite of cardiovascular death or worsening heart failure in patients with obesity-related HFpEF and improved health status [68].”
Tiwari, D., Lau, C. S., & Aw, T. C. (2026) · LabMed · doi:10.3390/labmed3040024
Eisa, N., & Khoury, M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag284
Qin, S.-S., Wu, Z.-M., Bao-shi, Z., & Luo, C. (2026) · World Journal of Cardiology · doi:10.4330/wjc.125519
Cline, L. (2026) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001370
Ye, X., Wu, Q., Li, L., Huang, M., & Wang, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1955431
Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine
Kanoia, S. B., Tiwari, A., Rizvi, S. W. A., & Tiwari, A. (2026) · Journal of Pharmaceutical and Biopharmaceutical Research · doi:10.25082/jpbr.2026.01.004
“In heart failure with preserved ejection fraction and obesity, semaglutide improved symptoms and physical limitation (STEP-HFpEF, n = 529) [19], and tirzepatide reduced the composite of cardiovascular death or worsening heart failure (SUMMIT, n = 731; HR 0.62, 0.41–0.95) [ 20].”
InfluentialKrasniqi, L., Hamandi, M., Mortensen, P. E., Nissen, H., Pellikka, P. A., Borlaug, B. A., Gerke, O., Haujir, A., Krasniqi, L. O., Terkelsen, C. J., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag313
Self-citationKierzkowski, F., Skrzypek, W., Bryl, W., Paczkowska, A., & Hoffmann, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1977433
“Cardiovascular disease (CVD) and chronic kidney disease (CKD) are among the most clinically important complications associated with type 2 diabetes (T2D) and obesity.”
InfluentialTaha, A. R., El‐Bassossy, H. M., Eassa, S., Sabry, S. A., & Elbatreek, M. H. (2026) · Scientific Reports · doi:10.1038/s41598-026-71986-1
Park, H., Lee, N., & Park, S. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0064
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Halpern, B., Baur, L. A., Blüher, M., Jackson-Morris, A. M., Ralston, J., & Ryan, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00234-2 · Cited by 1
Tani, Y., Kagami, K., Yuasa, N., Harada, T., Murakami, T., Okuno, T., Yoshino, S., Yamada, E., Wada, N., Ishii, H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0041
Demidova, T. Y., & Izmaylova, M. Y. (2026) · National Health Care (Russia) · doi:10.47093/2713-069x.2026.7.2.18-26
Arslan, F. S., Ahmad, R., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001504
Young, C. F., George, N., Olson, A., & Diana, I. (2026) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2026.22.2.3
Nzobokela, J., Choolwe, S. C., & Masenga, S. K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1987811
PAH in the era of obesity: navigating phenotypes of pulmonary hypertension
Tager, D., Bernardo, R. J., & Tonelli, A. R. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2753850
Jang, R., Jang, M., Ruan, X., Jin, C., & Kim, W. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04199-0
“Additionally, decreases in inflam - matory biomarkers in both SELECT and SUMMIT further suggest an anti-inflammatory effect, which may be medi - ated through weight loss and/or more direct modulation of immune pathways [6, 7, 10, 31].”
InfluentialUÇUCU YAĞLARIN TERAPÖTİK POTANSİYELİ VE KLİNİK TRANSLASYONU: ETKİLİLİKTEN GÜVENLİLİĞE
Ayhan, İ. (2026) · Bidge Yayınları eBooks · doi:10.70269/10.70269/9961581285
Suzuki, S., Izawa, H., Kuwahara, K., Sakata, Y., Onishi, K., OKADA, Y., Okumura, T., SATO, Y., Sawamura, A., Hanatani, A., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.09.036
Inflammation and heart failure. Pathophysiological mechanisms and recent data
Αντωνόπουλος, Β. Γ. (2026) · University of Thessaly Institutional Repository (University of Thessaly)
Павловна, П. О., & Сергеевич, А. А. (2026) · Endocrinology News Opinions Training
Srivastava, N., Mehrotra, S., Biswas, S., Jain, A., & Dixit, R. K. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20263801
Koufakis, T., Tentolouris, A., Manthou, E., Teperikidis, L., Mylonas, A., Kotsa, K., & Doumas, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03829-4
Constrained oxidative reserve in heart failure with preserved ejection fraction
Ganya, W., Maarman, G. J., Essop, M. F., & Mazaza, A. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.90271.2026
Zeng, X., Cao, J., Xin, W., Harrison, K., Wan, Y., Slevin, E., 吕莉霞, Terzidis, K., Klaunig, J. E., & Meng, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119996
Kaşkal, M., Alam, U., & Lip, G. Y. H. (2026) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001262
Fernández‐Cisnal, A., Lorenzo, M., Palau, P., & Núñez, J. E. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107617
Koufakis, T. (2026) · Incretin Research and Therapeutics · doi:10.1016/j.irt.2026.100001
Kwaśny, A., Słoma-Krześlak, M., Uchmanowicz, I., Lee, C. S., Vellone, E., Juárez‐Vela, R., Surma, S., Labudda, M., & Czapla, M. (2026) · Nutrients · doi:10.3390/nu18213527
From Receptor Architecture to Outcome Maturity: A Clinical Framework for Multiorgan Incretin Therapy
Sztanek, F., Lőrincz, H., Nagy, A. C., & Harangi, M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.10.013
Grudniewska, A., Mrozikiewicz‐Rakowska, B., Wiszniewski, K., Filipiak, K. J., & Kuryłowicz, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219692
Zhang, J., 王永健, Li, J., Chen, Y., Peng, X., Thabane, L., Lip, G. Y. H., & Li, G. (2026) · Drugs · doi:10.1007/s40265-026-02409-8
Velasco, M. Á. P., Trenas, A., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez-Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107663
Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction
Selvaganesan, P., Karnib, M., Helmy, I., Zakeri, R., Saeed, Y. B., Sahadevan, J., Osman, M. N., Mondal, A., LaForest, S., Fang, J. C.-T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.050387
Doma, M., Ramadan, A., Yazdanpanah, M. H., Naeem, F., Ptaszek, L. M., & Ruskin, J. N. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.101003
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
“The STEP-HFpEF (semaglutide) [ 95] and SUM-MIT (tirzepatide) [96 ] trials showed significant improve - ments in HFpEF measures with incretin-mimetic therapy compared to placebo.”
InfluentialAlbuquerque, L. D. F., Guaina, M. A. A., & Rezende, G. D. O. (2026) · Revista Tópicos · doi:10.70773/revistatopicos/793388584
GLP-1 receptor agonists: heart failure medications that also produce weight loss?
Litwin, S. E., Shah, S. H., & Lam, C. S. P. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag848
Self-citationChotalia, R., Ghias, O., Shah, M. U., Hills, C. E., Ward, J. K., Squires, P. E., Andrews, R., Venugopal, V., Lee, K., & Gulsin, G. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2757946
Rahni, S., Lebovics, E., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001527
Gan, A., & Butoi, E. D. (2026) · Sci · doi:10.3390/sci8110327
Exploration of the Pathogenesis and Treatment of Heart Failure
Wen, B., Yang, S., & Wang, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm52463
Skelin, M., Perkov-Stipičin, B., Bračić, V., Škugor, Z., & Krečak, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71511
Araszkiewicz, A., Cyganek, K., Cypryk, K., CYRANKA, K., Czupryniak, L., Dąbrowski, M., Dzida, G. J., Gawrecki, A., Głowińska‐Olszewska, B., Grabski, B., et al. (2026) · Current Topics in Diabetes · doi:10.5114/ctd/226021
Osmanlli, A., Conforto, R., Roy, J., Hardersen, J., & Li, Z. (2026) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2026-0216
El‐Sheikh, M., Bandholm, T., Jørgensen, N. B., Ulrik, C. S., Barløse, M., Møller, S., Siebner, H. R., Grand, J., Barasa, A., Petersen, M., et al. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105216
Wang, Y., Li, X., Huang, Z., Duan, A., Wang, Q., Gao, L., Li, S., Zhao, Q., Yang, T., Zhao, Z., et al. (2026) · Clinical Cardiology · doi:10.1002/clc.70503
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.